VRDN
Income statement / Annual
Last year (2024), Viridian Therapeutics, Inc.'s total revenue was $302,000.00,
a decrease of 3.82% from the previous year.
In 2024, Viridian Therapeutics, Inc.'s net income was -$269.95 M.
See Viridian Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
Operating Revenue |
$302,000.00 |
$314,000.00 |
$1.77 M |
$2.96 M |
$1.05 M |
$4.46 M |
$8.39 M |
$4.00 M |
$3.34 M |
$2.54 M |
Cost of Revenue |
$0.00
|
$1.32 M
|
$755,000.00
|
$620,000.00
|
$28.30 M
|
$32.79 M
|
$30.42 M
|
$19.62 M
|
$2.55 M
|
$2.47 M
|
Gross Profit |
$302,000.00
|
-$1.01 M
|
$1.02 M
|
$2.34 M
|
-$27.25 M
|
-$28.33 M
|
-$22.04 M
|
-$15.62 M
|
$789,000.00
|
$66,000.00
|
Gross Profit Ratio |
1
|
-3.21
|
0.57
|
0.79
|
-25.96
|
-6.35
|
-2.63
|
-3.9
|
0.24
|
0.03
|
Research and Development Expenses |
$238.25 M
|
$159.77 M
|
$100.89 M
|
$56.89 M
|
$28.30 M
|
$34.79 M
|
$30.42 M
|
$19.62 M
|
$888,000.00
|
$1.00 M
|
General & Administrative Expenses |
$61.08 M
|
$95.00 M
|
$35.18 M
|
$25.81 M
|
$13.27 M
|
$11.65 M
|
$11.05 M
|
$10.91 M
|
$7.91 M
|
$7.69 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.67 M
|
$2.56 M
|
Selling, General & Administrative Expenses |
$61.08 M
|
$95.00 M
|
$35.18 M
|
$25.81 M
|
$13.27 M
|
$11.65 M
|
$11.05 M
|
$10.91 M
|
$9.58 M
|
$10.25 M
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$69.86 M
|
$0.00
|
$0.00
|
$0.00
|
$2.83 M
|
$0.00
|
Operating Expenses |
$299.34 M
|
$254.76 M
|
$136.08 M
|
$82.69 M
|
$41.57 M
|
$46.44 M
|
$41.47 M
|
$30.54 M
|
$10.46 M
|
$11.25 M
|
Cost And Expenses |
$299.34 M
|
$254.76 M
|
$136.08 M
|
$82.69 M
|
$41.57 M
|
$46.44 M
|
$41.47 M
|
$30.54 M
|
$13.01 M
|
$13.73 M
|
Interest Income |
$32.13 M
|
$18.56 M
|
$4.92 M
|
$318,000.00
|
$173,000.00
|
$941,000.00
|
$1.25 M
|
$403,000.00
|
$0.00
|
$0.00
|
Interest Expense |
$3.05 M
|
$1.85 M
|
$486,000.00
|
$3,000.00
|
$508,000.00
|
$835,000.00
|
$873,000.00
|
$383,000.00
|
$95,000.00
|
$141,000.00
|
Depreciation & Amortization |
$540,000.00
|
$522,000.00
|
$755,000.00
|
$620,000.00
|
$539,000.00
|
$288,000.00
|
$281,000.00
|
$308,000.00
|
$341,000.00
|
$184,000.00
|
EBITDA |
-$266.36 M |
-$234.57 M |
-$128.63 M |
-$78.79 M |
-$109.67 M |
-$40.75 M |
-$31.55 M |
-$25.82 M |
-$12.51 M |
-$11.00 M |
EBITDA Ratio |
-882
|
-747.02
|
-73.02
|
-26.76
|
-38.42
|
-9.2
|
-3.8
|
-6.53
|
-2.84
|
-4.34
|
Operating Income Ratio |
-990.18
|
-810.35
|
-75.79
|
-26.91
|
-105.12
|
-9.41
|
-3.95
|
-6.63
|
-3.75
|
-4.41
|
Total Other Income/Expenses Net |
$29.09 M
|
$16.72 M
|
$4.43 M
|
$315,000.00
|
-$335,000.00
|
$106,000.00
|
$381,000.00
|
$20,000.00
|
-$166,000.00
|
-$141,000.00
|
Income Before Tax |
-$269.95 M
|
-$237.73 M
|
-$129.87 M
|
-$79.41 M
|
-$110.72 M
|
-$41.87 M
|
-$32.70 M
|
-$26.51 M
|
-$12.67 M
|
-$11.33 M
|
Income Before Tax Ratio |
-893.87
|
-757.11
|
-73.29
|
-26.8
|
-105.44
|
-9.39
|
-3.9
|
-6.62
|
-3.8
|
-4.46
|
Income Tax Expense |
$0.00
|
$0.00
|
-$4.43 M
|
$3,000.00
|
$269,000.00
|
$547,000.00
|
$1.25 M
|
$95,000.00
|
$95,000.00
|
$0.00
|
Net Income |
-$269.95 M
|
-$237.73 M
|
-$125.44 M
|
-$79.42 M
|
-$110.98 M
|
-$42.42 M
|
-$32.70 M
|
-$26.51 M
|
-$12.67 M
|
-$11.33 M
|
Net Income Ratio |
-893.87
|
-757.11
|
-70.79
|
-26.8
|
-105.7
|
-9.51
|
-3.9
|
-6.62
|
-3.8
|
-4.46
|
EPS |
-3.98 |
-5.31 |
-3.91 |
-6.66 |
-31.2 |
-20.31 |
-16.57 |
-20.66 |
-17.57 |
-21 |
EPS Diluted |
-3.98 |
-5.31 |
-3.91 |
-6.66 |
-31.2 |
-20.31 |
-16.57 |
-20.66 |
-17.57 |
-21 |
Weighted Average Shares Out |
$67.89 M
|
$44.76 M
|
$32.09 M
|
$11.92 M
|
$3.56 M
|
$2.09 M
|
$1.97 M
|
$1.28 M
|
$721,410.00
|
$539,445.00
|
Weighted Average Shares Out Diluted |
$67.89 M
|
$44.76 M
|
$32.09 M
|
$11.92 M
|
$3.56 M
|
$2.09 M
|
$1.97 M
|
$1.28 M
|
$721,410.00
|
$539,460.00
|
Link |
|
|
|
|
|
|
|
|
|
|